Click here to get full coverage on Pyxis Oncology, Inc. - MLQ.ai

Pyxis Oncology, Inc. - MLQ.ai

Click here to get full coverage on PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill

PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS)  ChartMill

PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill

Click here to get full coverage on PYXS: Mid-year data will highlight MICVO's efficacy and safety in head and neck cancer, supporting pivotal plans - TradingView

PYXS: Mid-year data will highlight MICVO's efficacy and safety in head and neck cancer, supporting pivotal plans  TradingView

PYXS: Mid-year data will highlight MICVO's efficacy and safety in head and neck cancer, supporting pivotal plans - TradingView

Click here to get full coverage on PYXS | Pyxis Oncology, Inc. Common Insider Trading - Quiver Quantitative

PYXS | Pyxis Oncology, Inc. Common Insider Trading  Quiver Quantitative

PYXS | Pyxis Oncology, Inc. Common Insider Trading - Quiver Quantitative

Click here to get full coverage on Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials - Stock Titan

Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials  Stock Titan

Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials - Stock Titan

Click here to get full coverage on Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives - simplywall.st

Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives  simplywall.st

Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives - simplywall.st

Click here to get full coverage on HC Wainwright & Co. maintains Pyxis Oncology (PYXS) buy recommendation - MSN

HC Wainwright & Co. maintains Pyxis Oncology (PYXS) buy recommendation  MSN

HC Wainwright & Co. maintains Pyxis Oncology (PYXS) buy recommendation - MSN

Click here to get full coverage on Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know  Yahoo Finance

Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - Yahoo Finance

Click here to get full coverage on Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU)  The Globe and Mail

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail

Click here to get full coverage on LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $6 - Moomoo

LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $6  Moomoo

LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $6 - Moomoo

Click here to get full coverage on PYXS: Mid-year data will clarify MICVO's efficacy, safety, and pivotal trial path in head and neck cancer - TradingView

PYXS: Mid-year data will clarify MICVO's efficacy, safety, and pivotal trial path in head and neck cancer  TradingView

PYXS: Mid-year data will clarify MICVO's efficacy, safety, and pivotal trial path in head and neck cancer - TradingView

Click here to get full coverage on Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan

Pyxis brings in former ImmunoGen dealmaker to advance MICVO  Stock Titan

Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan

Click here to get full coverage on Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data - Quiver Quantitative

Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data  Quiver Quantitative

Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data - Quiver Quantitative

Click here to get full coverage on PYXS: Mid-year data will highlight efficacy and safety of a novel ADC in head and neck cancer - TradingView

PYXS: Mid-year data will highlight efficacy and safety of a novel ADC in head and neck cancer  TradingView

PYXS: Mid-year data will highlight efficacy and safety of a novel ADC in head and neck cancer - TradingView

Click here to get full coverage on Cancer drug developer Pyxis Oncology plans investor webcasts - Stock Titan

Cancer drug developer Pyxis Oncology plans investor webcasts  Stock Titan

Cancer drug developer Pyxis Oncology plans investor webcasts - Stock Titan

Click here to get full coverage on PYXS: MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping - TradingView

PYXS: MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping  TradingView

PYXS: MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping - TradingView

Click here to get full coverage on Pyxis Oncology (PYXS) Q1 2026 loss deepens as MICVO trials expand and cash runway tightens - Stock Titan

Pyxis Oncology (PYXS) Q1 2026 loss deepens as MICVO trials expand and cash runway tightens  Stock Titan

Pyxis Oncology (PYXS) Q1 2026 loss deepens as MICVO trials expand and cash runway tightens - Stock Titan

Click here to get full coverage on PYXS: MICVO demonstrates high response rates and safety advances in head and neck cancer trials - TradingView

PYXS: MICVO demonstrates high response rates and safety advances in head and neck cancer trials  TradingView

PYXS: MICVO demonstrates high response rates and safety advances in head and neck cancer trials - TradingView

Click here to get full coverage on Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan

Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS)  Stock Titan

Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan

Click here to get full coverage on Cancer-drug maker Pyxis lines up key 2026 MICVO trial readouts - Stock Titan

Cancer-drug maker Pyxis lines up key 2026 MICVO trial readouts  Stock Titan

Cancer-drug maker Pyxis lines up key 2026 MICVO trial readouts - Stock Titan

Click here to get full coverage on New Analyst Forecast: $PYXS Given $5 Price Target | PYXS Stock News - Quiver Quantitative

New Analyst Forecast: $PYXS Given $5 Price Target | PYXS Stock News  Quiver Quantitative

New Analyst Forecast: $PYXS Given $5 Price Target | PYXS Stock News - Quiver Quantitative

Click here to get full coverage on Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions - Yahoo Finance

Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions  Yahoo Finance

Pyxis Oncology, Inc.'s (NASDAQ:PYXS) top owners are retail investors with 39% stake, while 21% is held by institutions - Yahoo Finance

Click here to get full coverage on Pyxis fills head and neck cancer study, says cash lasts into Q4 - Stock Titan

Pyxis fills head and neck cancer study, says cash lasts into Q4  Stock Titan

Pyxis fills head and neck cancer study, says cash lasts into Q4 - Stock Titan

Click here to get full coverage on Pyxis Oncology (PYXS) Gets a Buy from Guggenheim - The Globe and Mail

Pyxis Oncology (PYXS) Gets a Buy from Guggenheim  The Globe and Mail

Pyxis Oncology (PYXS) Gets a Buy from Guggenheim - The Globe and Mail

Click here to get full coverage on We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully - Yahoo Finance

We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully  Yahoo Finance

We Think Pyxis Oncology (NASDAQ:PYXS) Needs To Drive Business Growth Carefully - Yahoo Finance

Click here to get full coverage on Pyxis Oncology Reports First Quarter 2026 Financial Results - GlobeNewswire

Pyxis Oncology Reports First Quarter 2026 Financial Results  GlobeNewswire

Pyxis Oncology Reports First Quarter 2026 Financial Results - GlobeNewswire

Click here to get full coverage on Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire

Pyxis Oncology to Participate in Upcoming Investor Conferences  GlobeNewswire

Pyxis Oncology to Participate in Upcoming Investor Conferences - GlobeNewswire

Click here to get full coverage on Pyxis Oncology Insiders Recover Some Losses, Which Stand At US$65k - simplywall.st

Pyxis Oncology Insiders Recover Some Losses, Which Stand At US$65k  simplywall.st

Pyxis Oncology Insiders Recover Some Losses, Which Stand At US$65k - simplywall.st

Click here to get full coverage on PYXS: Strong clinical progress and financial stability with pivotal MICVO data expected in 2026 - TradingView

PYXS: Strong clinical progress and financial stability with pivotal MICVO data expected in 2026  TradingView

PYXS: Strong clinical progress and financial stability with pivotal MICVO data expected in 2026 - TradingView

Click here to get full coverage on Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com

Pyxis Oncology stock plummets after early-stage cancer drug data  Investing.com

Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com

Click here to get full coverage on Pyxis Oncology Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Pyxis Oncology Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Pyxis Oncology Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com

Pyxis Oncology stock price target raised to $7 by H.C. Wainwright  Investing.com

Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com

Click here to get full coverage on Pyxis Oncology, Inc. (PYXS) stock price prediction 2026–2030 - Bitget

Pyxis Oncology, Inc. (PYXS) stock price prediction 2026–2030  Bitget

Pyxis Oncology, Inc. (PYXS) stock price prediction 2026–2030 - Bitget

Click here to get full coverage on Pyxis Oncology And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Pyxis Oncology And 2 Other Promising Penny Stocks To Watch  Yahoo Finance

Pyxis Oncology And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Click here to get full coverage on Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - GlobeNewswire

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer  GlobeNewswire

Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - GlobeNewswire

Click here to get full coverage on Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com

Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data  Investing.com

Guggenheim reiterates Buy on Pyxis Oncology stock ahead of trial data - Investing.com

Click here to get full coverage on Pyxis Oncology Announces Interim CEO Appointment and - GlobeNewswire

Pyxis Oncology Announces Interim CEO Appointment and  GlobeNewswire

Pyxis Oncology Announces Interim CEO Appointment and - GlobeNewswire

Click here to get full coverage on Pyxis Oncology stock (US70611B1026): steady Nasdaq trading ahead of valuation focus - AD HOC NEWS

Pyxis Oncology stock (US70611B1026): steady Nasdaq trading ahead of valuation focus  AD HOC NEWS

Pyxis Oncology stock (US70611B1026): steady Nasdaq trading ahead of valuation focus - AD HOC NEWS

Click here to get full coverage on Pyxis Oncology appoints Thomas Civik as interim CEO - Investing.com

Pyxis Oncology appoints Thomas Civik as interim CEO  Investing.com

Pyxis Oncology appoints Thomas Civik as interim CEO - Investing.com

Click here to get full coverage on Pyxis Oncology Appoints Thomas Civik as Interim CEO - citybiz

Pyxis Oncology Appoints Thomas Civik as Interim CEO  citybiz

Pyxis Oncology Appoints Thomas Civik as Interim CEO - citybiz

Click here to get full coverage on Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com

Pyxis Oncology director Humphrey sells $15917 in shares  Investing.com

Pyxis Oncology director Humphrey sells $15917 in shares - Investing.com

Click here to get full coverage on Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation - simplywall.st

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation  simplywall.st

Here's Why We're Watching Pyxis Oncology's (NASDAQ:PYXS) Cash Burn Situation - simplywall.st

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Creative Global Technology Holdings And 2 Other Promising Penny Stocks - simplywall.st

Creative Global Technology Holdings And 2 Other Promising Penny Stocks  simplywall.st

Creative Global Technology Holdings And 2 Other Promising Penny Stocks - simplywall.st

Click here to get full coverage on FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC - OncLive

FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC  OncLive

FDA Grants Fast Track Designation to PYX-201 for Recurrent/Metastatic HNSCC - OncLive

Click here to get full coverage on Pyxis Oncology announces retirement of CFO and COO Pamela Connealy - Investing.com

Pyxis Oncology announces retirement of CFO and COO Pamela Connealy  Investing.com

Pyxis Oncology announces retirement of CFO and COO Pamela Connealy - Investing.com

Click here to get full coverage on Pyxis Oncology stock (US70611B1026): Q1 2026 loss widens to $23.3M - AD HOC NEWS

Pyxis Oncology stock (US70611B1026): Q1 2026 loss widens to $23.3M  AD HOC NEWS

Pyxis Oncology stock (US70611B1026): Q1 2026 loss widens to $23.3M - AD HOC NEWS

Click here to get full coverage on Pyxis Oncology (PYXS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $PYXS - MarketBeat

Pyxis Oncology (PYXS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $PYXS  MarketBeat

Pyxis Oncology (PYXS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $PYXS - MarketBeat

Click here to get full coverage on Pyxis Oncology stock (US70611B1026): Builds $540M cash pile after Q1 loss - AD HOC NEWS

Pyxis Oncology stock (US70611B1026): Builds $540M cash pile after Q1 loss  AD HOC NEWS

Pyxis Oncology stock (US70611B1026): Builds $540M cash pile after Q1 loss - AD HOC NEWS

Click here to get full coverage on Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - citybiz

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets  citybiz

Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets - citybiz

Click here to get full coverage on PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors - OncLive

PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors  OncLive

PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors - OncLive

Click here to get full coverage on PYXS Stock Price and Chart — NASDAQ:PYXS - TradingView

PYXS Stock Price and Chart — NASDAQ:PYXS  TradingView

PYXS Stock Price and Chart — NASDAQ:PYXS - TradingView

Click here to get full coverage on Pyxis Oncology (PYXS) Stock Forecast and Price Target 2026 $PYXS - MarketBeat

Pyxis Oncology (PYXS) Stock Forecast and Price Target 2026 $PYXS  MarketBeat

Pyxis Oncology (PYXS) Stock Forecast and Price Target 2026 $PYXS - MarketBeat

Click here to get full coverage on Pyxis Oncology Stock Price Forecast. Should You Buy PYXS? - StockInvest.us

Pyxis Oncology Stock Price Forecast. Should You Buy PYXS?  StockInvest.us

Pyxis Oncology Stock Price Forecast. Should You Buy PYXS? - StockInvest.us

Click here to get full coverage on What is the current Price Target and Forecast for Pyxis Oncology (PYXS) - Zacks Investment Research

What is the current Price Target and Forecast for Pyxis Oncology (PYXS)  Zacks Investment Research

What is the current Price Target and Forecast for Pyxis Oncology (PYXS) - Zacks Investment Research

Click here to get full coverage on Pyxis Oncology (PYXS) - Zacks Investment Research

Pyxis Oncology (PYXS)  Zacks Investment Research

Pyxis Oncology (PYXS) - Zacks Investment Research

Click here to get full coverage on FDA grants fast track status to Pyxis’ PYX-201 - Pharmaceutical Technology

FDA grants fast track status to Pyxis’ PYX-201  Pharmaceutical Technology

FDA grants fast track status to Pyxis’ PYX-201 - Pharmaceutical Technology

Click here to get full coverage on PYXS Forecast — Price Prediction for 2026. Should I Buy PYXS? - Intellectia AI

PYXS Forecast — Price Prediction for 2026. Should I Buy PYXS?  Intellectia AI

PYXS Forecast — Price Prediction for 2026. Should I Buy PYXS? - Intellectia AI

Click here to get full coverage on PYXS Forecast — Price Target — Prediction for 2027 - TradingView

PYXS Forecast — Price Target — Prediction for 2027  TradingView

PYXS Forecast — Price Target — Prediction for 2027 - TradingView

Click here to get full coverage on Should I buy Pyxis Oncology (PYXS) - Zacks Investment Research

Should I buy Pyxis Oncology (PYXS)  Zacks Investment Research

Should I buy Pyxis Oncology (PYXS) - Zacks Investment Research

Click here to get full coverage on Pyxis Oncology (PYXS) Stock Price, News & Analysis $PYXS - MarketBeat

Pyxis Oncology (PYXS) Stock Price, News & Analysis $PYXS  MarketBeat

Pyxis Oncology (PYXS) Stock Price, News & Analysis $PYXS - MarketBeat

Click here to get full coverage on Pyxis Oncology (PYXS) Short Interest & Short Float | Updated Jun 2026 $PYXS - MarketBeat

Pyxis Oncology (PYXS) Short Interest & Short Float | Updated Jun 2026 $PYXS  MarketBeat

Pyxis Oncology (PYXS) Short Interest & Short Float | Updated Jun 2026 $PYXS - MarketBeat

Click here to get full coverage on Pyxis Oncology (PYXS) Earnings Date and Reports 2026 $PYXS - MarketBeat

Pyxis Oncology (PYXS) Earnings Date and Reports 2026 $PYXS  MarketBeat

Pyxis Oncology (PYXS) Earnings Date and Reports 2026 $PYXS - MarketBeat

Click here to get full coverage on Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference  The Manila Times

Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - The Manila Times

Click here to get full coverage on Is Pyxis Oncology (PYXS) Stock a Buy Now | Price at $1.45, Down 2.03% - Synthetic Long - newsline.com

Is Pyxis Oncology (PYXS) Stock a Buy Now | Price at $1.45, Down 2.03% - Synthetic Long  newsline.com

Is Pyxis Oncology (PYXS) Stock a Buy Now | Price at $1.45, Down 2.03% - Synthetic Long - newsline.com

Click here to get full coverage on Pyxis Oncology (PYXS) Stock: Jumps +3.17%, Approaching $2.39 2026-05-17 - Call Spread Alert - The Legal Advocate

Pyxis Oncology (PYXS) Stock: Jumps +3.17%, Approaching $2.39 2026-05-17 - Call Spread Alert  The Legal Advocate

Pyxis Oncology (PYXS) Stock: Jumps +3.17%, Approaching $2.39 2026-05-17 - Call Spread Alert - The Legal Advocate

Click here to get full coverage on PYXS Q1 2026 Earnings: Better-than-Expected Loss Highlights Progress in Oncology Pipeline - Revenue Report - The Legal Advocate

PYXS Q1 2026 Earnings: Better-than-Expected Loss Highlights Progress in Oncology Pipeline - Revenue Report  The Legal Advocate

PYXS Q1 2026 Earnings: Better-than-Expected Loss Highlights Progress in Oncology Pipeline - Revenue Report - The Legal Advocate

Click here to get full coverage on Pyxis Oncology (PYXS) Stock: Jumps +3.17%, Approaching $2.39 2026-05-17 - AAII Bullish - The Legal Advocate

Pyxis Oncology (PYXS) Stock: Jumps +3.17%, Approaching $2.39 2026-05-17 - AAII Bullish  The Legal Advocate

PYXS

Price Chart

Key Statistics

Technicals

About PYXS

Latest News

Pyxis Oncology, Inc. - MLQ.ai

PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill

PYXS: Mid-year data will highlight MICVO's efficacy and safety in head and neck cancer, supporting pivotal plans - TradingView

Advanced Charts

Top Gainers

Top Losers